© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.
May 3rd 2021
A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.
Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.
Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.
A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.
Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.